Arvinas Licenses Global Rights for VEPPANU to Rigel for $85M Upfront, up to $320M Milestones
ARVN sits 72% above its 52-week low of $5.9.
Summary
Arvinas has entered a global licensing agreement with Rigel Pharmaceuticals for its FDA-approved drug VEPPANU, securing $85 million in upfront and transition payments, plus potential milestones and royalties.
Key Events · M&A and Partnerships · ARVN
-
Global Licensing Deal for VEPPANU
Arvinas and Pfizer have licensed exclusive global development, manufacturing, and commercialization rights for VEPPANU (vepdegestrant) to Rigel Pharmaceuticals, Inc.
-
Significant Upfront and Transition Payments
Arvinas will receive $42.5 million in immediate cash ($35 million upfront and $7.5 million upon successful completion of transition activities) from the total $85 million paid by Rigel, split evenly with Pfizer.
-
Potential Future Milestones and Royalties
Arvinas is eligible for up to an additional $160 million in development, regulatory, and commercial milestone payments, plus tiered royalties in the mid-teens to mid-20s on worldwide net sales (Arvinas's share).
-
Strategic Focus on Pipeline and Cash Runway
This agreement allows Arvinas to reduce commercialization risk for VEPPANU and invest in its early-stage pipeline, aligning with its stated goal of maintaining a strong cash runway.
Analysis · ARVN · Life Sciences
This agreement provides Arvinas with a substantial immediate cash infusion and future revenue streams from its recently FDA-approved drug, VEPPANU, while transferring commercialization responsibilities and risks to Rigel. This strategic move allows Arvinas to strengthen its balance sheet and focus resources on its early-stage pipeline, extending its cash runway.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 381 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARVN was trading at $10.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $617.9M. The 52-week trading range was $5.90 to $14.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.